Chemoprevention of Barrett's esophagus and oral leukoplakia.
Garewal
H S
HS
University of Arizona Cancer Center, Tucson.
D000230:Adenocarcinoma / Q000453:epidemiology / Q000517:prevention & control*; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000188:drug therapy* / Q000453:epidemiology; D015415:Biomarkers; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000517:prevention & control*; D002338:Carotenoids / Q000627:therapeutic use; D000518:Eflornithine / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D007972:Leukoplakia, Oral / Q000188:drug therapy*; D009062:Mouth Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D009955:Ornithine Decarboxylase / Q000032:analysis; D010610:Pharyngeal Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D010865:Pilot Projects; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000453:epidemiology; D015995:Prevalence; D012176:Retinoids / Q000627:therapeutic use; D012189:Retrospective Studies
D016588:Anticarcinogenic Agents; D015415:Biomarkers; D012176:Retinoids; D002338:Carotenoids; D009955:Ornithine Decarboxylase; D000518:Eflornithine